Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

In the face of growing global healthcare challenges, breast cancer remains a key area of ​​concern due to its increasing prevalence worldwide. The Global Breast Cancer Therape ...

Arvinas, along with its partner Pfizer, cancelled plans for a Phase 3 trial combining its PROTAC vepdegestrant with its CDK4 ...

Arvinas (NASDAQ:ARVN) stock drops 33% after announcing workforce cuts and trial removals, despite beating earnings ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

More and better kinds of screening as well as new, more targeted treatments are making breast cancer less deadly.

The risk of cardiotoxicity may vary across CDK4/6 inhibitors, according to a study of patients with breast cancer published in the Journal of the National Comprehensive Cancer Network.

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

Highlights from Prelude’s efforts to discover and develop selective KAT6A degraders, including preclinical data, demonstrating potential for a differentiated efficacy and safety profile ...